Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, lung disorder, lung neoplasm, neoplasm, neoplastic meningitis, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, tumor of meninges	Recruiting	Not applicable	2025-03-06		NCT06643000

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Henan Cancer Hospital	147

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Henan Cancer Hospital	Zhengzhou	China	98
Henan Cancer Hospital	Zhengzhou	China	67